Eutilex.Co.,Ltd

KOSDAQ:A263050 Stock Report

Market Cap: ₩70.2b

Eutilex.Co.Ltd Valuation

Is A263050 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A263050 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A263050's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A263050's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A263050?

Key metric: As A263050 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A263050. This is calculated by dividing A263050's market cap by their current revenue.
What is A263050's PS Ratio?
PS Ratio10.2x
Sales₩6.89b
Market Cap₩70.24b

Price to Sales Ratio vs Peers

How does A263050's PS Ratio compare to its peers?

The above table shows the PS ratio for A263050 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.6x
A348150 KoBioLabs
1.6xn/a₩99.6b
A217330 Cytogen
17.2xn/a₩106.1b
A314130 Genome
3.4xn/a₩82.4b
A317690 QuantaMatrix
24.3xn/a₩91.0b
A263050 Eutilex.Co.Ltd
10.2xn/a₩70.2b

Price-To-Sales vs Peers: A263050 is good value based on its Price-To-Sales Ratio (10.2x) compared to the peer average (11.6x).

Price to Sales Ratio vs Industry

How does A263050's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
A006280 GC Biopharma
1.2x9.1%US$1.36b
A096530 Seegene
2.7x15.7%US$735.40m
A086900 Medy-Tox
3.5x14.2%US$570.55m
A005250 Green Cross Holdings
0.4xn/aUS$550.70m
A263050 10.2xIndustry Avg. 11.7xNo. of Companies27PS01632486480+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A263050 is good value based on its Price-To-Sales Ratio (10.2x) compared to the KR Biotechs industry average (11.7x).

Price to Sales Ratio vs Fair Ratio

What is A263050's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A263050 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A263050's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:36
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eutilex.Co.,Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Taehee KimMirae Asset Securities Co., Ltd.
Wan KuNH Investment & Securities Co., Ltd.